Researchers combined DOTAP-mediated hydrophobic ion pairing with microfluidic mixing to load semaglutide into cetyl palmitate solid lipid nanoparticles. The lead F10 formulation, using a 1:18 semaglutide-to-DOTAP molar ratio and 10% w/w peptide loading, produced sub-300 nm particles with…
Researchers have formulated semaglutide into cetyl palmitate solid lipid nanoparticles using DOTAP-mediated hydrophobic ion pairing and microfluidic mixing in a herringbone device. The lead formulation, F10, uses a 1:18 semaglutide-to-DOTAP molar ratio and a 10% w/w peptide concentration. It produces particles below 300 nm in size with almost complete encapsulation, and it raises apparent permeability across Caco-2 intestinal epithelial monolayers by approximately 6-fold relative to free semaglutide.
The finding matters because oral semaglutide delivery has to clear three obstacles at once: limited gastrointestinal stability, poor epithelial permeability, and low affinity for lipid-based delivery systems. A marketed oral form of semaglutide already exists, but it depends on an absorption-enhancing excipient, a workaround at the mucosal surface rather than protection of the peptide itself. The new approach addresses the problem earlier in the chain by converting the peptide into a lipophilic ion pair and housing it in a solid lipid matrix.
All of the evidence so far is in vitro. The study used Caco-2 monolayers for permeability testing and a mucin network for mucus interaction, and it describes no animal or human subjects. The authors frame the approach as potentially promising rather than clinically validated, a distinction that matters for anyone reading the permeability result as a step toward a product.
The research team screened semaglutide-to-DOTAP molar ratios from 1:0 to 1:18. F10 is the product of that screen: a 1:18 ratio with 10% w/w peptide loading. The formulation achieved a particle size below 300 nm, almost complete encapsulation efficiency, and a highly positive zeta potential. The study reports no exact percentage for encapsulation efficiency and no numeric value for zeta potential, so F10 cannot yet be benchmarked quantitatively against other carriers.
The chemistry is a two-step handoff. DOTAP, a cationic lipid with a permanently charged quaternary ammonium head group, forms an electrostatic complex with semaglutide, masking the peptide's charge and raising its affinity for oil phases. That hydrophobic ion pair is then incorporated into cetyl palmitate, a wax ester that is solid at body temperature and forms an ordered lipid crystal lattice. Without the ion-pairing step, semaglutide is too hydrophilic to stay in the lipid matrix, which is the stated reason the strategy exists.
Production runs through a microfluidic herringbone mixer. Herringbone grooves create chaotic advection inside the channel, forcing the lipid and peptide streams to mix rapidly and uniformly at the microscale. Compared with bulk emulsification, this gives tighter control of particle nucleation and growth, and because mixing occurs in continuous flow, the process is more readily scaled than batch methods. Fourier transform infrared spectroscopy, differential scanning calorimetry, thermogravimetric analysis, and small-angle X-ray scattering confirmed that the ion pair formed and that the peptide was incorporated into the lipid matrix rather than adsorbed onto the surface.
The functional profile follows from the structure. F10 was stable under simulated gastrointestinal conditions, released semaglutide in a sustained manner, interacted strongly with mucus, and still retained the ability to diffuse through the mucin network. Cytocompatibility studies showed acceptable cell viability at relevant concentrations. Together those data describe a particle that survives the gut, stays near the absorptive surface, and does not simply sit on top of the mucus.
The study is a preclinical formulation investigation, not a clinical one. Its study population consists of in vitro models only: Caco-2 monolayers for epithelial permeability and a mucin network for mucus interaction. No sample size and no study duration are reported, which is normal for a formulation characterization study but worth stating plainly because it sets expectations about the strength of the evidence.
The endpoint list is broad for a particle study. It covers particle size, zeta potential, encapsulation efficiency, morphology, solid-state organization, colloidal stability, release behavior, mucus interaction, cytocompatibility, and epithelial permeability. Each endpoint answers a distinct question a formulation scientist would ask before advancing a carrier: Is the particle small enough? Is it charged the way the design predicts? Is the drug inside or outside? Does it hold together under gastrointestinal stress? Does it release at a usable rate? Does it harm cells? Does it cross an epithelium better than the free peptide? F10 delivers a coherent positive result on each count, with the permeability gain as the headline number.
What the design can and cannot show needs to be precise. Caco-2 cells are the standard intestinal absorption model in pharmaceutical development. They polarize into monolayers with tight junctions, express brush border enzymes, and predict human absorption reasonably well for passively transported compounds. But they lack a full mucus layer, which is why the study added a separate mucin network model to test whether positively charged particles adhere to mucus or move through it. The finding that F10 does both, interacting strongly while retaining mucodiffusion, is the balance an oral carrier needs. Even so, a 6-fold gain over a poorly absorbed peptide in cells leaves the absolute fraction absorbed in a human unknown. That number can only come from pharmacokinetic studies in animals and then in people.
Semaglutide is a large acylated peptide. It is a GLP-1 receptor agonist engineered with a fatty diacid chain attached through a hydrophilic spacer, a modification that allows albumin binding and a long circulating half-life. The same design that gives semaglutide its duration of action complicates oral dosing: the molecule is too large to diffuse through membranes, it carries ionizable groups that keep it hydrophilic, and it is vulnerable to gastric acid and pepsin, to pancreatic and brush border proteases, and to the enzymatic load of the small intestine.
The F10 carrier attacks each barrier with a different mechanism. Encapsulation in the solid lipid matrix shields the peptide from proteolytic attack. The highly positive zeta potential promotes electrostatic interaction with negatively charged mucin, which extends residence time at the absorptive surface. The approximately 6-fold increase in Caco-2 permeability suggests that the particle either delivers protected peptide close to the membrane, facilitates transport across it, or both. The study does not establish which mechanism dominates, and the distinction will matter as the formulation is optimized further.
Hydrophobic ion pairing is the enabling step. Peptide and cationic lipid combine stoichiometrically, charge is neutralized, and the apparent lipophilicity of the peptide rises enough to make it compatible with a lipid phase. The screen from 1:0 to 1:18 shows the team hunting for the ratio where complexation is complete without letting the cationic lipid dominate the particle surface. At ratios below that point, the peptide is not fully masked; above it, excess DOTAP would change charge, size, and release behavior in ways that could undermine the balance the team was seeking. The 1:18 point is therefore presented as the optimized balance, not an arbitrary cap.
The formulation work lands inside a much larger clinical story. Peptide Atlas holds records for 668 registered clinical trials for semaglutide. The phase breakdown on file lists 4 trials in Phase 2, 4 trials in Phase 4, and 1 trial in Phase 3, with 10 trials currently recruiting. The distribution skews toward early proof-of-concept and post-marketing work, which is typical of a drug whose core indications are mature and whose expansion is driven by repurposing.
The recruiting trials show where that expansion is heading. NCT07586150, the LIFETRAIN study, evaluates personalized pharmaco-lifestyle interventions in severe mental illness, including major depressive disorder and bipolar disorder. NCT07430332, a Phase 2 trial, examines a GLP-1 receptor agonist in stage 1 type 1 diabetes. NCT07614412, SHIELD-T1D, a Phase 2 trial, studies a GLP-1 agonist together with Shingrix for beta-cell preservation in recent-onset type 1 diabetes. NCT07462663, SHAPE-ENDO, is a Phase 4 pilot trial of multimodal pre-surgical optimization versus standard surgery in patients with obesity and early-stage endometrial cancer. NCT07027969, a Phase 4 trial, tests metabolic surgery for atrial fibrillation elimination. NCT06977438, a Phase 4 trial, evaluates a GLP-1 plus lifestyle program in childhood obesity. Psychiatry, oncology, cardiology, and endocrinology are all present in that list.
The indexed literature on file runs to 197 PubMed papers. Recent entries include a systematic review of long-term safety and renal outcomes in non-diabetic obesity with chronic kidney disease or hypertension PMID 42340790, Clin Ter, 2026-07-01 , a systematic review of weight-lowering drugs and natural female fertility PMID 42307450, Clin Obes, 2026-07-01 , a randomized clinical trial of semaglutide and effort-based decision-making in major depressive disorder PMID 42054055, JAMA Psychiatry, 2026-07-01 , the STRIDE trial of semaglutide in peripheral artery disease and diabetes by baseline disease severity and age PMID 41780559, Eur Heart J, 2026-07-01 , and a scoping review of the risk of retinal vascular events in patients using semaglutide PMID 42348481, Ophthalmologica, 2026-06-25 . Delivery science is a smaller slice of this output than safety and repurposing, which is one reason a formulation study like this one stands out.
Supply-chain records add a practical note. Peptide Atlas files eight third-party laboratory purity tests for semaglutide, with the highest observed purity at 99.979%. A reference page at https://peptideatlas.co/peptides/semaglutide aggregates the trial, literature, and quality data. Formulation studies sit on top of that quality foundation; a carrier cannot be judged fairly if the peptide starting material varies between batches.
For formulation scientists, the useful output is the recipe. The 1:18 semaglutide-to-DOTAP ratio, the 10% w/w loading, and the cetyl palmitate matrix are concrete, reproducible parameters. The herringbone microfluidic mixer is commercially available technology, and the characterization suite of FTIR, DSC, TGA, and SAXS is standard in pharmaceutics laboratories. The general sequence, pair the peptide with a counterion, load it into a solid lipid, then test against mucus and epithelial models, transfers directly to other poorly permeable, lipid-incompatible peptides beyond semaglutide.
For clinicians, the immediate implications are modest, and they should be. No prescribing decision can follow from Caco-2 data. But the direction of the research is clinically meaningful: an oral semaglutide that protects the peptide through the gut rather than relying on a mucosal absorption enhancer could change dosing schedules, adherence, and tolerability. Those are hypotheses. They become findings only after pharmacokinetic and clinical data exist.
For the supply chain, the signals are scalability and purity. Microfluidic mixing is a continuous process, generally easier to scale reproducibly than batch emulsification, and the excipients involved, DOTAP and cetyl palmitate, are commodity lipids. The peptide is the cost driver, which makes starting-material quality decisive: a formulation study can only be reproduced if the peptide…
Peptides referenced: Semaglutide, GLP-1.
Related reading: Peptide self-assembly death pathways classified into five themes, GLP-1 Initiation Tied to Fewer Coded GI Symptoms in IBS, GLP-1 Receptor Agonists Tied to Lower Pseudarthrosis Odds After ACDF, Semaglutide Slows Proteomic Dementia Risk Signature in SELECT Analysis.